Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Short term Debt (2016 - 2022)

Marker Therapeutics (MRKR) has disclosed Short term Debt for 6 consecutive years, with $2.5 million as the latest value for Q4 2022.

  • Quarterly Short term Debt changed N/A to $2.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2022, changed N/A year-over-year, with the annual reading at $2.5 million for FY2022, N/A changed from the prior year.
  • Short term Debt for Q4 2022 was $2.5 million at Marker Therapeutics, down from $5.0 million in the prior quarter.
  • The five-year high for Short term Debt was $8.0 million in Q2 2022, with the low at $8000.0 in Q1 2018.
  • Average Short term Debt over 3 years is $1.5 million, with a median of $107000.0 recorded in 2018.
  • The sharpest move saw Short term Debt skyrocketed 1683.33% in 2018, then tumbled 55.78% in 2019.
  • Over 3 years, Short term Debt stood at $49000.0 in 2018, then crashed by 36.73% to $31000.0 in 2019, then skyrocketed by 7964.52% to $2.5 million in 2022.
  • According to Business Quant data, Short term Debt over the past three periods came in at $2.5 million, $5.0 million, and $8.0 million for Q4 2022, Q3 2022, and Q2 2022 respectively.